[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575595":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":17,"responsibleParty":30,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":19,"whyStopped":7,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Vincenzo Russo, MD","PRINCIPAL_INVESTIGATOR",[13],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","+390512144747","vincenzo.russo@aosp.bo.it",[18],{"facility":5,"status":19,"city":20,"state":7,"zip":21,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":7},"RECRUITING","Bologna","40138","Italy","IT",{"type":25,"coordinates":26},"Point",[27,28],11.33875,44.49381,{"lat":28,"lon":27},{"type":31,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100575595","role-of-spectral-ct-in-the-evaluation-of-cardiotoxicity-in-patients-with-hodgkins-lymphoma-and-diffuse-large-b-cell-lymphoma-treated-with-anthracyclines-100575595",false,"NCT06774326","Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines","AntraCardioTox","Inclusion Criteria:\n\n* Patients with Hodgkin's lymphoma or diffuse large B-cell lymphoma (DLBCL) undergoing treatment regimens including anthracyclines\n* Age ≥18 years\n* Informed consent obtained\n\nExclusion Criteria:\n\n* Absolute or relative contraindications to CT examination and\u002For administration of iodinated contrast agents (e.g., pregnancy, severe renal insufficiency in non-dialysis patients with GFR \\\u003C15-30 ml\u002Fmin\u002F1.73m²).\n* Patients with a concomitant positive history of cardiovascular disease (e.g., myocardial infarction, known coronary artery disease, heart failure, arrhythmias, prior myocarditis, cardiomyopathies).\n* History of mediastinal radiotherapy.","ALL","18 Years",{"count":42,"type":43},160,"ESTIMATED","OBSERVATIONAL","To evaluate the diagnostic capability of Spectral CT (performed with contrast agent as part of routine oncological follow-up) in detecting signs of acute and chronic early-onset cardiac toxicity from anthracyclines in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing treatment regimens that include a drug from this family.",[47,48,49,50],"Cardiac Imaging","Cardiac Imaging Techniques","Lymphoma","Hodgkin Disease","2025-01-09",{"date":53,"type":54},"2025-01-14","ACTUAL",{"date":56,"type":54},"2024-02-14",{"date":58,"type":43},"2029-08",{"name":5,"class":6},1]